Severe myopericarditis following induction therapy with idarubicin and transretinoic acid in a patient with acute promyelocytic leukemia
Med Clin (Barc). 2018 Jun 22;150(12):492-493.
doi: 10.1016/j.medcli.2017.10.030.
Epub 2017 Nov 28.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Farmacia, Hospital Clínic de Barcelona, Barcelona, España. Electronic address: ecarcele@clinic.cat.
- 2 Servicio de Farmacia, Hospital Clínic de Barcelona, Barcelona, España.
No abstract available
MeSH terms
-
Adult
-
Anti-Inflammatory Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Arsenic Trioxide / administration & dosage
-
Cardiovascular Agents / therapeutic use
-
Chest Pain / etiology
-
Drug Substitution
-
Echocardiography
-
Electrocardiography
-
Humans
-
Idarubicin / administration & dosage
-
Idarubicin / adverse effects*
-
Leukemia, Promyelocytic, Acute / drug therapy*
-
Male
-
Myocarditis / chemically induced*
-
Myocarditis / diagnostic imaging
-
Myocarditis / drug therapy
-
Pericarditis / chemically induced*
-
Pericarditis / diagnostic imaging
-
Pericarditis / drug therapy
-
Remission Induction
-
Tretinoin / administration & dosage
-
Tretinoin / adverse effects*
Substances
-
Anti-Inflammatory Agents
-
Cardiovascular Agents
-
Tretinoin
-
Arsenic Trioxide
-
Idarubicin